Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-181-2 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Only standard information required at REACH Annex VIII is available for assessing the toxicokinetics for the test substance. The available test data do not permit extensive conclusions concerning absorption, metabolism or excretion to be conclusively drawn. As the substance was deemed to be corrosive, minimal vertebrate studies have been conducted.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
The substance is a UVCB with many high-molecular weight components of which adsorption and systemic exposure would not be expected. However, repeated oral administration of the test substance (in an OECD 422 study) to rats provided a parental NOAEL of 250 mg/kg/day. This was based on minimal to mild atrophy of the thymus observed in half of the high dose (5 out of 10) females receiving 500 mg/kg/day, when compared to the controls. This lesion was characterized by thymic lymphocyte depletion correlated with reduced thymus size and weight. Also observed were epithelial changes ranging from focal or multifocal erosion of the glandular region of the stomach seen in a few high dose animals of both sexes at the high dose.
These and other minor changes indicate that the substance (or components of the substance) are likely to be adsorbed and enter systemic circulation. Based on the relatively low Log Kow values (<4.5), bioaccumulation of the test substance is not expected.
No adverse treatment related changes were observed in any of the developmental or reproductive parameters in the OECD 422 study, possibly indicating low adsorption through the placenta to directly affect the foetuses and similarly as no effects were observed in pups during the lactation phase, low exposure to the developing pups via lactation is likely.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
